1. Home
  2. TVTX vs STNE Comparison

TVTX vs STNE Comparison

Compare TVTX & STNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$42.68

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Logo StoneCo Ltd.

STNE

StoneCo Ltd.

HOLD

Current Price

$10.41

Market Cap

3.3B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TVTX
STNE
Founded
N/A
2012
Country
United States
Cayman Islands
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.3B
IPO Year
2013
2018

Fundamental Metrics

Financial Performance
Metric
TVTX
STNE
Price
$42.68
$10.41
Analyst Decision
Strong Buy
Buy
Analyst Count
13
7
Target Price
$40.62
$19.07
AVG Volume (30 Days)
2.7M
5.7M
Earning Date
05-04-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
92.89
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$44.76
$15.07
Revenue Next Year
$35.51
$6.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.88
$10.26
52 Week High
$48.61
$19.95

Technical Indicators

Market Signals
Indicator
TVTX
STNE
Relative Strength Index (RSI) 62.11 28.05
Support Level $26.97 N/A
Resistance Level $48.61 $15.80
Average True Range (ATR) 2.21 0.42
MACD -0.28 -0.15
Stochastic Oscillator 36.23 4.44

Price Performance

Historical Comparison
TVTX
STNE

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

About STNE StoneCo Ltd.

StoneCo Ltd is a provider of financial technology solutions. It serves MSMBs solutions, at fair prices, and provides the customer experience to help them manage their businesses and sell more. Its Stone Business Model combines end-to-end, cloud-based technology platforms; differentiated hyper-local and integrated distribution approaches; and white-glove, on-demand customer service. It has two segments Financial Services segment, which includes payments solutions, digital banking, credit, insurance solutions as well as the registry business. In the Software segment solution includes POS/ERP, TEF and QR Code gateways, reconciliation, CRM, OMS, e-commerce platform, engagement tool, ads solution, and marketplace hub. It generates the majority of its revenue from the Financial Services segment.

Share on Social Networks: